FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 337:572-573 August 21, 1997 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Sano, M. PubMed Citation

To the Editor: Sano et al. (April 24 issue)¹ conclude that alpha-tocopherol and selegiline are effective in slowing the progression of moderately severe Alzheimer's disease. Did they prove a true effect of treatment, or can the result be reasonably attributed to bias arising in the design, performance, or analysis of the trial?

Presumably, they designed and performed their study as a double-blind, randomized, controlled trial in order to reduce bias. The verdict of the unadjusted analysis, which did not show a statistically significant advantage in any of the treatment groups, was not accepted. When they used the Cox proportional-hazards model . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Vatassery, G. T, Bauer, T., Dysken, M. (1999). High doses of vitamin E in the treatment of disorders of the central nervous system in the aged. Am. J. Clin. Nutr. 70: 793-801 [Abstract] [Full Text]